组织型纤溶酶原激活剂：冠状动脉内应用
Tissue-type plasminogen activator: intracoronary applications.
作者信息
Tiefenbrunn A J
机构信息
Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.
出版信息
Cathet Cardiovasc Diagn. 1990 Feb;19(2):108-15. doi: 10.1002/ccd.1810190210.
PMID:2106393
Abstract
Intracoronary tissue-type plasminogen activator (t-PA) was employed successfully before, after, or in place of coronary artery angioplasty in four patients referred for emergency cardiac catheterization during evolving myocardial infarction. The potential roles of intracoronary thrombolysis, dose considerations for intracoronary t-PA, factors influencing the choice of plasminogen activator, and safety issues are discussed.
摘要
在4例因进展性心肌梗死而接受紧急心脏导管插入术的患者中，冠状动脉内组织型纤溶酶原激活剂（t-PA）已成功地在冠状动脉血管成形术前、术后或替代血管成形术时应用。本文讨论了冠状动脉内溶栓的潜在作用、冠状动脉内t-PA的剂量考量、影响纤溶酶原激活剂选择的因素以及安全性问题。
相似文献
1
Tissue-type plasminogen activator: intracoronary applications.组织型纤溶酶原激活剂：冠状动脉内应用
Cathet Cardiovasc Diagn. 1990 Feb;19(2):108-15. doi: 10.1002/ccd.1810190210.
2
Clinical experience with intracoronary tissue plasminogen activator: results of a multicenter registry. Intracoronary t-PA Registry Investigators.
Cathet Cardiovasc Diagn. 1995 Mar;34(3):196-201. doi: 10.1002/ccd.1810340104.
3
Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.组织型纤溶酶原激活剂治疗与直接冠状动脉血管成形术：对无并发症心肌梗死后1个月心肌组织灌注和局部功能的影响
J Am Coll Cardiol. 1998 Feb;31(2):338-43. doi: 10.1016/s0735-1097(97)00487-7.
4
Systemic thrombolysis for early intracoronary stent thrombosis.早期冠状动脉内支架血栓形成的全身溶栓治疗。
Lancet. 1995 Jul 8;346(8967):119-20. doi: 10.1016/s0140-6736(95)92142-7.
5
Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty.
Am J Cardiol. 1991 Dec 15;68(17):1609-13. doi: 10.1016/0002-9149(91)90317-e.
6
Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction?重组组织型纤溶酶原激活剂（rt-PA）：它是正在进展的急性心肌梗死的首选溶栓剂吗？
Am J Cardiol. 1987 Apr 15;59(9):984-9. doi: 10.1016/0002-9149(87)91139-8.
7
Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.重组组织型纤溶酶原激活剂冠状动脉溶栓治疗。冠状动脉内给药与静脉内给药对比。
Chest. 1991 Jul;100(1):201-6. doi: 10.1378/chest.100.1.201.
8
Intracoronary tenecteplase in STEMI with massive thrombus.急性ST段抬高型心肌梗死伴大量血栓时冠状动脉内注射替奈普酶
Indian Heart J. 2018 May-Jun;70(3):446-449. doi: 10.1016/j.ihj.2017.08.016. Epub 2017 Aug 26.
9
[Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].[溶栓剂、尿激酶、组织型纤溶酶原激活剂和尿激酶原——它们的给药途径和剂量：冠状动脉内溶栓与静脉冠状动脉溶栓的比较]
Nihon Rinsho. 2003 Apr;61 Suppl 4:441-5.
10
Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
J Am Coll Cardiol. 1991 Aug;18(2):613-20. doi: 10.1016/0735-1097(91)90621-f.
引用本文的文献
1
Concomitant Myocardial Infarction and Stroke Managed With a Unique Approach: A Case Report and Review of Literature.采用独特方法治疗的心肌梗死与中风并存病例：病例报告及文献综述
Cureus. 2025 Jan 27;17(1):e78073. doi: 10.7759/cureus.78073. eCollection 2025 Jan.
Zotero 插件